Mifsud E - Search Results

1

Diabetes and Overweight/Obesity Are Independent, Nonadditive Risk Factors for In-Hospital Severity of COVID-19: An International, Multicenter Retrospective Meta-analysis.

Longmore DK, Miller JE, Bekkering S, Saner C, Mifsud E, Zhu Y, Saffery R, Nichol A, Colditz G, Short KR, Burgner DP; International BMI-COVID consortium. Longmore DK, et al. Among authors: mifsud e. Diabetes Care. 2021 Jun;44(6):1281-1290. doi: 10.2337/dc20-2676. Epub 2021 Apr 15. Diabetes Care. 2021. PMID: 33858854 Free PMC article.

2

Reducing the impact of influenza-associated secondary pneumococcal infections.

Mifsud EJ, Tan AC, Short KR, Brown LE, Chua BY, Jackson DC. Mifsud EJ, et al. Immunol Cell Biol. 2016 Jan;94(1):101-8. doi: 10.1038/icb.2015.71. Epub 2015 Jul 21. Immunol Cell Biol. 2016. PMID: 26134269

3

Epidemiology of repeat influenza infection in Queensland, Australia, 2005-2017.

Price O, Birrell FA, Mifsud EJ, Sullivan SG. Price O, et al. Among authors: mifsud ej. Epidemiol Infect. 2022 Jul 18;150:e144. doi: 10.1017/S0950268822001157. Epidemiol Infect. 2022. PMID: 35843721 Free PMC article.

4

Intranasal administration of the TLR2 agonist Pam2Cys provides rapid protection against influenza in mice.

Tan AC, Mifsud EJ, Zeng W, Edenborough K, McVernon J, Brown LE, Jackson DC. Tan AC, et al. Among authors: mifsud ej. Mol Pharm. 2012 Sep 4;9(9):2710-8. doi: 10.1021/mp300257x. Epub 2012 Aug 3. Mol Pharm. 2012. PMID: 22823162

5

TLR Agonists as Modulators of the Innate Immune Response and Their Potential as Agents Against Infectious Disease.

Mifsud EJ, Tan AC, Jackson DC. Mifsud EJ, et al. Front Immunol. 2014 Mar 3;5:79. doi: 10.3389/fimmu.2014.00079. eCollection 2014. Front Immunol. 2014. PMID: 24624130 Free PMC article. Review.

6

Generation of Adaptive Immune Responses Following Influenza Virus Challenge is Not Compromised by Pre-Treatment with the TLR-2 Agonist Pam2Cys.

Mifsud EJ, Tan AC, Brown LE, Chua BY, Jackson DC. Mifsud EJ, et al. Front Immunol. 2015 Jun 5;6:290. doi: 10.3389/fimmu.2015.00290. eCollection 2015. Front Immunol. 2015. PMID: 26097481 Free PMC article.

7

Mapping the pulmonary environment of animals protected from virulent H1N1 influenza infection using the TLR-2 agonist Pam₂Cys.

Mifsud EJ, Tan AC, Reading PC, Jackson DC. Mifsud EJ, et al. Immunol Cell Biol. 2016 Feb;94(2):169-76. doi: 10.1038/icb.2015.81. Epub 2015 Aug 14. Immunol Cell Biol. 2016. PMID: 26272554

8

Inactivated Influenza Vaccine That Provides Rapid, Innate-Immune-System-Mediated Protection and Subsequent Long-Term Adaptive Immunity.

Chua BY, Wong CY, Mifsud EJ, Edenborough KM, Sekiya T, Tan AC, Mercuri F, Rockman S, Chen W, Turner SJ, Doherty PC, Kelso A, Brown LE, Jackson DC. Chua BY, et al. Among authors: mifsud ej. mBio. 2015 Oct 27;6(6):e01024-15. doi: 10.1128/mBio.01024-15. mBio. 2015. PMID: 26507227 Free PMC article.

9

Tear Interferon-Gamma as a Biomarker for Evaporative Dry Eye Disease.

Jackson DC, Zeng W, Wong CY, Mifsud EJ, Williamson NA, Ang CS, Vingrys AJ, Downie LE. Jackson DC, et al. Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):4824-4830. doi: 10.1167/iovs.16-19757. Invest Ophthalmol Vis Sci. 2016. PMID: 27654409

10

Inactivated whole virus particle vaccine with potent immunogenicity and limited IL-6 induction is ideal for influenza.

Sekiya T, Mifsud EJ, Ohno M, Nomura N, Sasada M, Fujikura D, Daito T, Shingai M, Ohara Y, Nishimura T, Endo M, Mitsumata R, Ikeda T, Hatanaka H, Kitayama H, Motokawa K, Sobue T, Suzuki S, Itoh Y, Brown LE, Ogasawara K, Kino Y, Kida H. Sekiya T, et al. Among authors: mifsud ej. Vaccine. 2019 Apr 3;37(15):2158-2166. doi: 10.1016/j.vaccine.2019.02.057. Epub 2019 Mar 8. Vaccine. 2019. PMID: 30857932

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

33 results

Search Page